METTL16 and acute myeloid leukemia: Mechanistic studies show that METTL16 exerts its oncogenic effects by promoting the expression of branched‐chain amino acid (BCAA) transaminase 1 (BCAT1) and BCAT2 in an m6A‐dependent manner, thereby reprogramming BCAA metabolism in AML.226